All News Abivax

Equities

ABVX

FR0012333284

Real-time Euronext Paris Other stock markets 06:08:34 29/04/2024 pm IST			5-day change	1st Jan Change
15.16 ^EUR	+2.29%		+5.28%	+54.38%

01:22pm	Piper Sandler Starts Abivax With Overweight Rating, $42 Price Target	MT
01:22pm	Guggenheim Starts Abivax With Buy Rating, $50 Price Target	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Starts Abivax With Overweight Rating, $42 Price Target	04:52pm	MT
Guggenheim Starts Abivax With Buy Rating, $50 Price Target	04:52pm	MT
Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating	11/04	MT
Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024	08/04
Abivax publishes financial reports with the French and U.S. securities regulatory agencies	08/04	AQ
Abivax publishes financial reports with the French and U.S. securities regulatory agencies	06/04	EQ
ABIVAX Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Abivax reports 2023 financial results and operational update	02/04	EQ
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn's and Colitis Organization (ECCO)	14/02	AQ
Abivax: presentation on obefazimod at the ECCO congress	13/02	CF
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)	13/02	EQ
ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality	08/02	CI
Abivax appoints new head of quality	07/02	CF
Abivax appoints Ana Sharma as Vice President, Global Head of Quality	07/02	EQ
Transcript : ABIVAX Société Anonyme - Special Call	07/02
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease	05/02	AQ
Abivax Modifies Trial Design of Phase 2b Development Program After US FDA Feedback	02/02	MT
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease	02/02	EQ
Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn?s Disease	02/02	CI
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024	24/01	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Abivax

Equities

ABVX

FR0012333284

All News

Filters